A Phase I Study of Hydroxychloroquine With or Without Erlotinib in Advanced Non-Small Cell Lung Cancer.

Trial Profile

A Phase I Study of Hydroxychloroquine With or Without Erlotinib in Advanced Non-Small Cell Lung Cancer.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 26 Nov 2014

At a glance

  • Drugs Erlotinib (Primary) ; Hydroxychloroquine (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 08 Aug 2012 Primary endpoint 'Maximum-tolerated-dose' has been met.
    • 08 Aug 2012 Final results published in the Journal of Thoracic Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top